BioNexus Gene Lab Corp. (BGLC)
OTCMKTS: BGLC · Delayed Price · USD
0.614
+0.013 (2.23%)
May 1, 2024, 4:00 PM EDT - Market closed
BioNexus Gene Lab Revenue
In the year 2023, BioNexus Gene Lab had annual revenue of $9.77M, a decrease of -10.60%. Revenue in the quarter ending December 31, 2023 was $2.27M, a -19.95% decrease year-over-year.
Revenue (ttm)
$9.77M
Revenue Growth
-10.60%
P/S Ratio
1.12
Revenue / Employee
$325,694
Employees
30
Market Cap
10.93M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 9.77M | -1.16M | -10.60% |
Dec 31, 2022 | 10.93M | -2.43M | -18.21% |
Dec 31, 2021 | 13.36M | 1.97M | 17.31% |
Dec 31, 2020 | 11.39M | 11.26M | 8,872.03% |
Dec 31, 2019 | 126.96K | -85.37K | -40.21% |
Dec 31, 2018 | 212.33K | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
BHP Group | 55.34B |
Rio Tinto Group | 54.04B |
Vale S.A. | 41.78B |
CRH plc | 34.95B |
Linde | 32.85B |
The Sherwin-Williams Company | 23.05B |
Freeport-McMoRan | 22.86B |
Ecolab | 15.32B |
BGLC News
- 13 days ago - BioNexus Gene Lab Corp. Agrees to Invest RM 1.2 million in Ascension Innovation (AISB) to Advance Digital Health Innovation through AI adoption in Healthcare - GlobeNewsWire
- 10 months ago - BioNexus Gene Lab Corp. Announces Closing of $5.75 Million Public Offering and Full Exercise of Over-Allotment Option and Uplisting to the Nasdaq Capital Market - GlobeNewsWire
- 10 months ago - BioNexus Gene Lab Corp. Announces Pricing of $5 Million Public Offering and Uplisting to the Nasdaq Capital Market - GlobeNewsWire